Obstet Gynecol:产前使用糖皮质激素可降低妊娠24周前出生新生儿的死亡率

2016-03-20 Mechront 译 MedSci原创

近期发表在Obstetrics & Gynecology的文章称,产前使用糖皮质激素和积极的强化治疗,可降低妊娠24周前出生的新生儿的出院死亡率。加拿大麦克马斯特大学的Christina K. Park和同事检索了相关文献,纳入了17篇观察性研究进行了系统回顾,比较妊娠24周前出生的新生儿产前使用和不使用糖皮质激素的结局。该系统回顾共涉及了3626名新生儿,以出院死亡率作为主要结局。分析数

近期发表在Obstetrics & Gynecology的文章称,产前使用糖皮质激素和积极的强化治疗,可降低妊娠24周前出生的新生儿的出院死亡率。

加拿大麦克马斯特大学的Christina K. Park和同事检索了相关文献,纳入了17篇观察性研究进行了系统回顾,比较妊娠24周前出生的新生儿产前使用和不使用糖皮质激素的结局。

该系统回顾共涉及了3626名新生儿,以出院死亡率作为主要结局。分析数据显示,干预组和对照组出院死亡率分别为58.1%和71.8%,证据等级为中等。与对照组相比,产前使用糖皮质技术可显著降低新生儿的出院死亡率(OR=0.45;校正后OR=0.48)。严重发病率情况在两组间没有差异。

作者写道:“现有的可用的观察性研究数据显示,产前使用糖皮质激素和积极的强化治疗,可降低妊娠24周前出生的新生儿的出院死亡率。因此,对妊娠24周前有即刻分娩风险,且不选择放弃,要求产后紧急复苏的患者,可以选择使用糖皮质激素。”

原始出处:

Park, Christina K; Isayama, Tetsuya,et al.Antenatal Corticosteroid Therapy Before 24 Weeks of Gestation: A Systematic Review and Meta-analysis.Obstetrics & Gynecology.Post Author Corrections: March 07, 2016

Antenatal corticosteroids cut mortality for early preemies.MedicalXpress.March 16, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
    2016-03-30 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
    2016-03-22 qilu_qi
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2043900, encodeId=50a22043900e1, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 20 21:44:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011236, encodeId=be09201123653, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Wed Mar 30 03:44:00 CST 2016, time=2016-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701137, encodeId=e3191e0113772, content=<a href='/topic/show?id=b5f6e6827fb' target=_blank style='color:#2F92EE;'>#糖皮质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76827, encryptionId=b5f6e6827fb, topicName=糖皮质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f4230340116, createdName=Tommy1959, createdTime=Mon Aug 29 13:44:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502473, encodeId=698015024e3f3, content=<a href='/topic/show?id=ef4b2441971' target=_blank style='color:#2F92EE;'>#产前#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24419, encryptionId=ef4b2441971, topicName=产前)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b49a9545081, createdName=qilu_qi, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600241, encodeId=880f160024128, content=<a href='/topic/show?id=3565e21649e' target=_blank style='color:#2F92EE;'>#皮质激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72164, encryptionId=3565e21649e, topicName=皮质激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb1a18781011, createdName=bbwznl, createdTime=Tue Mar 22 12:44:00 CST 2016, time=2016-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=72446, encodeId=9c30e24464c, content=好文章啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon Mar 21 21:54:00 CST 2016, time=2016-03-21, status=1, ipAttribution=)]
    2016-03-21 milkshark

    好文章啊

    0

相关资讯

Ann Intern Med:社区获得性肺炎的住院患者应用皮质醇治疗的荟萃分析

背景:社区活动性肺炎(CAP)比较常见,并且病情较为严重。目的:为了调查CAP住院病人辅以糖皮质激素治疗后,对患者死亡率,发病率,住院时间的影响。数据来源:收集2015年5月24之前,MEDLINE, EMBASE以及Cochrane对照试验注册中心的数据。研究选择:CAP住院成年患者进行系统糖皮质激素治疗的随机试验。数据处理:患者出生时间的中位数为60年代,约60%患者为男性。辅以糖皮质激素治疗

八大类药物不可与糖皮质激素合用!

安全用药知识你具备了吗?有些药明明是治疗疾病的,但如果不慎搭配,会变成毒药,甚至会有致命的可能。像糖皮质激素类药物很多,广泛应用于治疗皮炎、过敏性疾病、活动性风湿病、类风湿性关节炎等。功效多多,但实际上有八种药物不能与之搭配。有些会使药效降低,有些则会加重病情。下面和大家一起学习辨别这8类药物,做到安全用药。糖皮质激素类药物主要有氢化可的松、泼尼松、泼尼松龙、地塞米松、甲泼尼龙、曲安奈德、倍他米松

Lancet:免疫性血小板减少症使用利妥昔单抗可改善治疗应答

原发免疫性血小板减少症(Immune thrombocytopenia,ITP)是一种免疫介导的自身抗体致敏的血小板被单核巨噬细胞系统破坏和血小板成熟释放障碍所致的疾病。虽然目前还相对缺乏利妥昔单抗(rituximab,美罗华)应用于ITP十分确切的治疗证据,利妥昔单抗作为一个未被临床指南正式认可的适用于本病治疗的药物也频繁应用于部分ITP患者当中,研究者在先前曾接受糖皮质激素免疫抑制治疗的未切脾

Ann intern med:糖皮质激素可有效治疗肺炎及并发症、死亡率

来自麦克玛斯特大学的一项研究表,皮质类固醇激素在治疗肺炎方面有着很大的优势,该研究成果在线发表于《内科学年鉴》。该研究第一作者Dr. Reed Siemieniuk说道,“我们的研究可导致一个肺炎治疗方案上的重要改变。糖皮质激素廉价且易获得,数以百万的肺炎患者将因我们的研究发现而受益。”世界上,下呼吸道感染是导致新生儿死亡的第二大常见病因。发达国家因社区获得性肺炎而住院的现象十分常见,而且与急性呼

2岁前吸入糖皮质激素治疗哮喘可能会导致今后儿童生长发育迟缓

糖皮质激素是当前防治哮喘最有效的药物,吸入糖皮质激素可有效控制哮喘症状。主要作用机制是抑制炎症细胞的迁移和活化;抑制细胞因子的生成;抑制炎症介质的释放;增强平滑肌细胞β2受体的反应性。可分为吸入、口服和静脉用药。 国际指南建议,婴儿吸入糖皮质激素只用于治疗复发性哮喘。哮喘发作一次或两次时,应使用短效支气管扩张剂治疗或短疗程口服糖皮质激素。然而,Antti Saari认为,现在使用激素出现滥用现象。

Diabetologia:糖皮质激素诱导的胰岛素抵抗降低肠促胰素效应

最近,有研究评估了在健康个体使用糖皮质激素诱导胰岛素抵抗造成进展性T2DM模型,评估肠促胰素效应。试验中,挑选19名健康、糖耐量正常的T2DM一级亲属作为受试者。 在地塞米松治疗前,所有受试者都要进行第1天的OGTT试验,接着是为期3天葡萄糖钳夹试验,分别向受试者静注GLP-1、GIP或NaCl,最后静注精氨酸来明确胰岛beta细胞的最大分泌功能。地塞米松治疗5天后,重复这4天的试验。总